Core Viewpoint - Getty Images Holdings, Inc. reported a quarterly loss of $0.08 per share, missing the Zacks Consensus Estimate of $0.03, and showing a significant decline from earnings of $0.01 per share a year ago, resulting in an earnings surprise of -366.67% [1][2] Financial Performance - The company posted revenues of $234.88 million for the quarter ended June 2025, which was 0.61% below the Zacks Consensus Estimate, but an increase from $229.14 million in the same quarter last year [2] - Over the last four quarters, Getty Images has not surpassed consensus EPS estimates and has only topped revenue estimates twice [2] Stock Performance - Shares of Getty Images have declined approximately 21.8% since the beginning of the year, contrasting with the S&P 500's gain of 8.6% [3] - The current Zacks Rank for Getty Images is 3 (Hold), indicating that the stock is expected to perform in line with the market in the near future [6] Earnings Outlook - The consensus EPS estimate for the upcoming quarter is $0.03 on revenues of $242.78 million, while the estimate for the current fiscal year is -$0.16 on revenues of $952.28 million [7] - The trend of earnings estimate revisions is mixed, which could change following the recent earnings report [6] Industry Context - The Internet - Software industry, to which Getty Images belongs, is currently ranked in the top 37% of over 250 Zacks industries, suggesting that companies in the top half tend to outperform those in the bottom half by more than 2 to 1 [8]

Core Insights - Perion Network (PERI) reported quarterly earnings of $0.26 per share, exceeding the Zacks Consensus Estimate of $0.17 per share, with an earnings surprise of +52.94% [1] - The company posted revenues of $102.98 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 1.49%, although this represents a decline from year-ago revenues of $108.69 million [2] - Perion Network shares have increased approximately 20.5% year-to-date, outperforming the S&P 500's gain of 8.6% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.26 on revenues of $110.5 million, and for the current fiscal year, it is $0.99 on revenues of $440.66 million [7] - The estimate revisions trend for Perion Network was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Internet - Content industry, to which Perion Network belongs, is currently ranked in the top 41% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Similarweb (SMWB), another company in the same industry, is expected to report a quarterly loss of $0.00 per share, with revenues projected at $68.88 million, reflecting a year-over-year increase of 13.6% [9]

Core Insights - Clearside Biomedical, Inc. reported a quarterly loss of $0.06 per share, outperforming the Zacks Consensus Estimate of a loss of $0.12, marking a 50% earnings surprise [1] - The company achieved revenues of $0.49 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 87.07%, compared to revenues of $0.09 million a year ago [2] - The stock has underperformed, losing approximately 59.7% since the beginning of the year, while the S&P 500 has gained 7.8% [3] Financial Performance - Over the last four quarters, Clearside Biomedical has surpassed consensus EPS estimates four times [2] - The current consensus EPS estimate for the upcoming quarter is -$0.08 on revenues of $0.26 million, and for the current fiscal year, it is -$0.38 on revenues of $3.22 million [7] Market Outlook - The company's earnings outlook is crucial for assessing future stock performance, with a favorable trend in estimate revisions leading to a Zacks Rank 2 (Buy) [6] - The Medical - Biomedical and Genetics industry is currently ranked in the bottom 43% of over 250 Zacks industries, which may impact stock performance [8]

Core Viewpoint - ProFrac Holding Corp. reported a quarterly loss of $0.67 per share, significantly worse than the Zacks Consensus Estimate of a loss of $0.29, marking an earnings surprise of -131.03% [1] Financial Performance - The company posted revenues of $501.9 million for the quarter ended June 2025, slightly exceeding the Zacks Consensus Estimate by 0.52%, but down from $579.4 million in the same quarter last year [2] - Over the last four quarters, ProFrac has surpassed consensus EPS estimates two times and topped revenue estimates three times [2] Stock Performance - ProFrac Holding Corp. shares have declined approximately 19.2% since the beginning of the year, contrasting with the S&P 500's gain of 7.9% [3] Future Outlook - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the next quarter is -$0.27 on revenues of $477.65 million, and for the current fiscal year, it is -$0.98 on revenues of $1.99 billion [7] Industry Context - The Oil and Gas - Field Services industry, to which ProFrac belongs, is currently ranked in the bottom 9% of over 250 Zacks industries, indicating a challenging environment [8]

Core Viewpoint - Arcosa (ACA) reported quarterly earnings of $1.27 per share, exceeding the Zacks Consensus Estimate of $1.05 per share, and showing an increase from $0.91 per share a year ago [1][2] Financial Performance - The earnings surprise for the quarter was +20.95%, with the company previously expected to earn $0.29 per share but actually earning $0.49, resulting in a surprise of +68.97% [2] - Arcosa's revenues for the quarter were $736.9 million, which missed the Zacks Consensus Estimate by 2.09%, compared to $664.7 million in the same quarter last year [3] - Over the last four quarters, the company has surpassed consensus EPS estimates three times but has only topped revenue estimates once [3] Stock Performance - Arcosa shares have declined approximately 12.5% since the beginning of the year, while the S&P 500 has gained 7.9% [4] - The company's current Zacks Rank is 3 (Hold), indicating expected performance in line with the market in the near future [7] Future Outlook - The consensus EPS estimate for the upcoming quarter is $1.32 on revenues of $778.3 million, and for the current fiscal year, it is $3.83 on revenues of $2.93 billion [8] - The outlook for the industry, specifically the Building Products - Miscellaneous sector, is currently in the bottom 37% of over 250 Zacks industries, which may impact stock performance [9]

Company Performance - Karat Packing (KRT) reported quarterly earnings of $0.57 per share, missing the Zacks Consensus Estimate of $0.60 per share, but showing an increase from $0.49 per share a year ago, resulting in an earnings surprise of -5.00% [1] - The company posted revenues of $123.99 million for the quarter ended June 2025, slightly missing the Zacks Consensus Estimate by 0.01%, and an increase from $112.6 million year-over-year [2] - Over the last four quarters, Karat Packing has surpassed consensus EPS estimates only once [2] Stock Outlook - The stock has underperformed the market, losing about 10.9% since the beginning of the year, while the S&P 500 gained 7.9% [3] - The current consensus EPS estimate for the coming quarter is $0.45 on revenues of $125 million, and for the current fiscal year, it is $1.59 on revenues of $462 million [7] Industry Context - The Containers - Paper and Packaging industry, to which Karat Packing belongs, is currently ranked in the bottom 21% of over 250 Zacks industries, indicating a challenging environment [8] - Empirical research suggests that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]

Company Performance - Vermilion Energy reported a quarterly loss of $0.2 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.06, representing an earnings surprise of -233.33% [1] - The company posted revenues of $320.77 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 26.71%, and down from $350.04 million a year ago [2] - Over the last four quarters, Vermilion has not surpassed consensus EPS estimates and has topped revenue estimates only once [2] Stock Movement and Outlook - Vermilion shares have declined approximately 16.4% since the beginning of the year, contrasting with the S&P 500's gain of 7.9% [3] - The company's earnings outlook is crucial for understanding future stock performance, with current consensus EPS estimates at $0.07 for the coming quarter and $0.29 for the current fiscal year [4][7] Industry Context - The Oil and Gas - Exploration and Production - International industry, to which Vermilion belongs, is currently ranked in the bottom 18% of over 250 Zacks industries, indicating potential challenges ahead [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Vermilion's stock performance [5]

Company Performance - Verastem reported a quarterly loss of $0.39 per share, which was better than the Zacks Consensus Estimate of a loss of $0.85, representing an earnings surprise of +54.12% [1] - The company posted revenues of $2.14 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 86.36%, compared to revenues of $10 million a year ago [2] - Over the last four quarters, Verastem has surpassed consensus EPS estimates two times but has not beaten consensus revenue estimates [2] Stock Movement and Outlook - Verastem shares have increased by approximately 10.6% since the beginning of the year, outperforming the S&P 500's gain of 7.9% [3] - The future stock price movement will largely depend on management's commentary during the earnings call and the company's earnings outlook [4][6] - The current consensus EPS estimate for the upcoming quarter is -$0.72 on revenues of $10.98 million, and for the current fiscal year, it is -$3.51 on revenues of $17.25 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Verastem belongs, is currently ranked in the top 41% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Verastem's performance [5]

Company Performance - Chesapeake Utilities reported quarterly earnings of $1.04 per share, exceeding the Zacks Consensus Estimate of $1 per share, and up from $0.86 per share a year ago, representing an earnings surprise of +4.00% [1] - The company posted revenues of $192.8 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 3.99%, compared to $166.27 million in the same quarter last year [2] - Over the last four quarters, Chesapeake Utilities has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Market Performance - Chesapeake Utilities shares have declined approximately 0.7% since the beginning of the year, while the S&P 500 has gained 7.9% [3] - The company's current Zacks Rank is 3 (Hold), indicating that shares are expected to perform in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.88 on revenues of $162.9 million, and for the current fiscal year, it is $6.27 on revenues of $885.2 million [7] - The outlook for the Utility - Gas Distribution industry is positive, currently ranking in the top 20% of over 250 Zacks industries, suggesting that the industry is likely to outperform the bottom 50% by a factor of more than 2 to 1 [8]

Core Viewpoint - AbCellera Biologics Inc. reported a quarterly loss of $0.12 per share, outperforming the Zacks Consensus Estimate of a loss of $0.17, indicating a positive earnings surprise of +29.41% [1] Financial Performance - The company posted revenues of $17.08 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 146.95%, compared to $7.32 million in the same quarter last year [2] - Over the last four quarters, AbCellera has surpassed consensus EPS estimates three times [2] Stock Performance - AbCellera shares have increased approximately 40.6% since the beginning of the year, significantly outperforming the S&P 500's gain of 7.9% [3] Future Outlook - The company's earnings outlook will be crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the next quarter is -$0.17 on revenues of $7.31 million, and for the current fiscal year, it is -$0.69 on revenues of $25.53 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which AbCellera belongs, is currently ranked in the top 41% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]